The goals of this clinical study are to identify if GS-4528 alone or in combination with
Anti-PD-1 Monoclonal Antibody is safe and tolerable in people with solid tumors and to
identify the recommended dose of GS-4528 for further development that is safe to give to
people alone or in combination with Anti-PD-1 Monoclonal Antibody.
The primary objectives of this study are:
- To assess the safety and tolerability of GS-4528 as monotherapy and in combination with
Anti-PD-1 Monoclonal Antibody (negative immunoregulatory human cell surface receptor
programmed cell death 1) in participants with advanced solid tumors.
- To identify the maximum tolerated dose (MTD)/maximum administered dose (MAD) and/or the
recommended Phase 2 dose (RP2D) of GS-4528 as monotherapy and in combination with
Anti-PD-1 Monoclonal Antibody in participants with advanced solid tumors.